The Effect of Intraoperative Tramadol on Postoperative Opioid

The Effect of Intraoperative Tramadol on Postoperative Opioid Requirements After Laparoscopic Sleeve Gastrectomy for Morbid Obese Patients (A Retrospective Multicentric Cohort Study)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05696886

Acronym

LSG

Enrollment

400

Registered

2023-01-25

Start date

2021-01-01

Completion date

2022-12-31

Last updated

2023-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

laparoscopic sleeve gastrectomy, morbid obesity, postoperative pain, tramadol, pethidine

Brief summary

Postoperative pain remains a very UNPLEASENTevent, particularly in morbidly obese patients that may be associated with obstructive sleep apnea. Bariatric surgery patients must get safe and efficient analgesia, which is essential given that up to 45 % of patients report substantial pain in the first two days following surgery. The study's purpose was to compare the efficacy and safety of combined tramadol with pethidine versus pethidine alone and to assess their impact on postoperative pethidine requirements after LSG for morbidly obese patients

Detailed description

This multicenter cohort research included patients with morbid obesity who had LSG between January 2021 and December 2022. The patients included in the study were allocated to one of two treatment groups that were not randomized but the patients were categorized according to the time of surgery: Group A received Pethidine alone in the period between January 2021 and December 2021, while Group B got Tramadol with pethidine in the period between January 2022 and December 2022. Doses were based on the patient's actual body weight.

Interventions

DRUGPethidine

Group A received Pethidine alone in the period between January 2021 and December 2021

DRUGTramadol with pethidine

Group B got Tramadol with pethidine in the period between January 2022 and December 2022

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

Group A received Pethidine alone in the period between January 2021 and December 2021, while Group B got Tramadol with pethidine in the period between January 2022 and December 2022. Doses were based on the patient's actual body weight.

Intervention model description

Eligibility

Sex/Gender

ALL

Age

16 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients with morbid obesity defined as a BMI of more than 40 or * BMI less than 35 with at least one comorbidity and * ages ranging from 16 to 65, were patients

Exclusion criteria

* Patients under the age of 16 or over 65, * Those with severe GERD, leakage * pregnancy, or * inflammatory bowel disease,

Design outcomes

Primary

Measure	Time frame	Description
VAS of pain	48 hours postoperative	the severity of pain
opioid requirement	one month	the need of pethidine

Secondary

Measure	Time frame	Description
hospital stay	one month	hospital stay

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026